Email Updates

You are here

Home

30 OCTOBER 2020 VOLUME 22 ISSUE 42

Media Coverage

  • Monoclonal Antibody Ibalizumab Maintains HIV Suppression for Nearly a Decade

    Ibalizumab (Trogarzo), a long-acting monoclonal antibody that prevents HIV from entering cells, kept HIV suppressed for up to ten years in people with highly resistant virus, researchers reported at the virtual IDWeek conference last week.

    October 29, 2020
    Antibody Related Research
    aidsmap

  • The Preexposure Prophylaxis Pipeline

    The CDC reports that adherence to preexposure prophylaxis (PrEP) reduces the risk of acquiring HIV from sex by about 99 percent and from injection drug use by at least 74 percent. Currently, only 2 medications are approved for use as PrEP: TDF /FTC (Truvada™) and TAF/FTC (Descovy™). Although tenofovir disoproxil fumarate/emtricitabine is currently approved for all adults in the prevention of sexually acquired HIV, tenofovir alafenamide/emtricitabine is approved only for prevention in men who have sex with men and in transgender women. Most importantly, efficacy of these oral products relies on strict adherence, which poses a challenge for many at-risk populations. To address this disparity, several investigational products are under development that incorporate a diverse armamentarium of options, analogous to contraceptives including but not limited to on-demand PrEP, non-oral formulations, and longer-acting agents.

    October 29, 2020
    Microbicides, Multipurpose Prevention Technologies, PrEP
    Contagion Live

  • Address Medical Mistrust to Recruit Minorities to COVID-19 Trials

    To end HIV and control COVID-19, medicine must earn back the trust of people in Black, Latinx, and Native American communities, said Jonathan Mermin, MD, MPH, director of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention at the CDC.

    October 29, 2020
    General
    Medscape

  • We Need to Talk About Racism as a Barrier to HIV Prevention and Care for Black Women

    HIV infection rates among Black women in the US have fallen sharply over the past decade—but look closer, and the numbers still paint a troubling story. Black women remain disproportionately impacted by HIV, with a higher risk of infection than women of any other race or ethnicity. If current rates persist, according to Centers for Disease Control and Prevention (CDC) estimates, one in 48 Black women may be diagnosed with HIV in their lifetime—compared with one in 227 Hispanic women and one in 880 white women.

    October 28, 2020
    PrEP, Treatment
    The BodyPro

  • People Are Still Having Sex. So Why Are STD Rates Dropping?

    For the first time in years, rates of chlamydia, gonorrhea and syphilis, which had been on track in 2020 to hit record highs in the United States, have taken an abrupt downturn.

    October 28, 2020
    General
    New York Times

  • Black People Risk Being ‘Left Behind’ in the Fight Against HIV As Prevention Drug Is Rolled Out in England

    As game-changing HIV-prevention pill PrEP is made available in England after a near-decade-long battle, the Terrence Higgins Trust is campaigning to raise awareness of the drug among Black Africans as diagnoses rise within the community.

    October 27, 2020
    PrEP
    inews

  • To End the HIV Epidemic Among Latinx Populations, Look at the Big Picture and Zoom In

    In February 2019, the federal government updated national HIV goals to end the epidemic in the US by 2030. Those goals appeared to be coming into reach because of significant overall progress in the fight against HIV, with deaths attributed to HIV across the US decreasing by approximately 4 percent from 2014 to 2018 and estimated new infections decreasing by 7 percent, reflecting improving access to prevention, treatment and care.

    October 27, 2020
    General
    Science Speaks

  • Acute HIV Cases Turn Up in COVID Screening

    Patients newly infected with HIV are being diagnosed in greater numbers because they are showing up at hospitals with symptoms similar to infection with SARS-CoV-2, researchers reported at the 2020 virtual IDWeek conference.

    October 26, 2020
    General
    MedPage Today

  • A New Strawberry-Flavoured HIV Treatment for Children Could Improve Adherence

    A new paediatric antiretroviral uses a fixed-dose treatment and child-friendly flavours to help parents administering HIV treatment to their children.

    October 26, 2020
    Treatment
    Health-E News

  • More Research Points to Weight Increases on TAF-Containing HIV Treatment

    Weight gain in people with HIV starting antiretroviral therapy has been a source of concern for years. Recently, however, that concern has shifted to a more narrow focus on two areas: One is the relatively recent class of integrase strand inhibitors (INSTI), and the other is the NRTI tenofovir alafenamide (TAF), which has generally been regarded as having a better long-term safety profile than tenofovir disoproxil fumarate (TDF, Viread).

    October 26, 2020
    PrEP, Treatment
    The BodyPro

  • Three Demands From the HIV Leaders of Black South Rising

    How can Black HIV leaders in the South better educate and mobilize their community against the epidemic? Answers are spelled out in manifesto issued by Black South Rising, a collective of advocates in the South focused on combating HIV through the lens of African-American experiences.

    October 23, 2020
    General
    POZ

Published Research

Announcements